1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 18, 11, 1, 1, 15, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Diabetic Foot Ulcers - Overview
- Diabetic Foot Ulcers - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Diabetic Foot Ulcers - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Diabetic Foot Ulcers - Companies Involved in Therapeutics Development
- Diabetic Foot Ulcers - Drug Profiles
- 3K3A-APC - Drug Profile
- Product Description
- Mechanism Of Action
- Amesanar - Drug Profile
- Product Description
- Mechanism Of Action
- AP-185 - Drug Profile
- Product Description
- Mechanism Of Action
- APO-2 - Drug Profile
- Product Description
- Mechanism Of Action
- ASCP-02 - Drug Profile
- Product Description
- Mechanism Of Action
- AUP-16 - Drug Profile
- Product Description
- Mechanism Of Action
- AV-001 - Drug Profile
- Product Description
- Mechanism Of Action
- BB-101 - Drug Profile
- Product Description
- Mechanism Of Action
- BFP-001 - Drug Profile
- Product Description
- Mechanism Of Action
- BFP-101 - Drug Profile
- Product Description
- Mechanism Of Action
- Biologic for Diabetic Foot Ulcers - Drug Profile
- Product Description
- Mechanism Of Action
- Cell Therapy for Diabetic Foot Ulcer - Drug Profile
- Product Description
- Mechanism Of Action
- Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
- Product Description
- Mechanism Of Action
- CHF-6467 - Drug Profile
- Product Description
- Mechanism Of Action
- Corlicyte - Drug Profile
- Product Description
- Mechanism Of Action
- CSA-144 - Drug Profile
- Product Description
- Mechanism Of Action
- CTX-001 - Drug Profile
- Product Description
- Mechanism Of Action
- CVBT-141 - Drug Profile
- Product Description
- Mechanism Of Action
- CVBT-141B - Drug Profile
- Product Description
- Mechanism Of Action
- CYP-006TK - Drug Profile
- Product Description
- Mechanism Of Action
- diperoxochloric acid - Drug Profile
- Product Description
- Mechanism Of Action
- donaperminogene seltoplasmid - Drug Profile
- Product Description
- Mechanism Of Action
- Drug for Diabetic Foot Ulcer - Drug Profile
- Product Description
- Mechanism Of Action
- ENERGIF-703 - Drug Profile
- Product Description
- Mechanism Of Action
- Epoetin alfa - Drug Profile
- Product Description
- Mechanism Of Action
- EscharEx - Drug Profile
- Product Description
- Mechanism Of Action
- EscharEx Second Generation - Drug Profile
- Product Description
- Mechanism Of Action
- esmolol hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- exeporfinium chloride - Drug Profile
- Product Description
- Mechanism Of Action
- FGF-1 - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy for Diabetic Foot Ulcers and Wound - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
- Product Description
- Mechanism Of Action
- ISN-001 - Drug Profile
- Product Description
- Mechanism Of Action
- MR-MC-01 - Drug Profile
- Product Description
- Mechanism Of Action
- MSC Exosomal Topical Suspension - Drug Profile
- Product Description
- Mechanism Of Action
- MT-003 - Drug Profile
- Product Description
- Mechanism Of Action
- Mul-1867 - Drug Profile
- Product Description
- Mechanism Of Action
- NORS-2791 - Drug Profile
- Product Description
- Mechanism Of Action
- Nu-3 - Drug Profile
- Product Description
- Mechanism Of Action
- OLX-106 - Drug Profile
- Product Description
- Mechanism Of Action
- PCSPH-08 - Drug Profile
- Product Description
- Mechanism Of Action
- PP-2351 - Drug Profile
- Product Description
- Mechanism Of Action
- RECCE-327 - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Human Platelet-Derived Growth Factor Gel - Drug Profile
- Product Description
- Mechanism Of Action
- recombinant plasminogen - Drug Profile
- Product Description
- Mechanism Of Action
- rhPDGF-BB - Drug Profile
- Product Description
- Mechanism Of Action
- ropocamptide - Drug Profile
- Product Description
- Mechanism Of Action
- RP-557 - Drug Profile
- Product Description
- Mechanism Of Action
- rusalatide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- SER-190 - Drug Profile
- Product Description
- Mechanism Of Action
- SLIF-06 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Diabetic Foot Ulcers - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit NOX for Diabetic Foot Ulcers - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Diabetic Foot Ulcers and Cystic Fibrosis - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Infected Diabetic Foot Ulcers - Drug Profile
- Product Description
- Mechanism Of Action
- SR-0379 - Drug Profile
- Product Description
- Mechanism Of Action
- Stem Cell Therapy for Diabetic Foot Ulcers - Drug Profile
- Product Description
- Mechanism Of Action
- Stem Cell Therapy for Diabetic Foot Ulcers, Injuries and Liver Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- Stempeucel - Drug Profile
- Product Description
- Mechanism Of Action
- suramin - Drug Profile
- Product Description
- Mechanism Of Action
- SymHeal - Drug Profile
- Product Description
- Mechanism Of Action
- tobramycin + triclosan - Drug Profile
- Product Description
- Mechanism Of Action
- TOPN-53 - Drug Profile
- Product Description
- Mechanism Of Action
- TP-102 - Drug Profile
- Product Description
- Mechanism Of Action
- TTAX-01 - Drug Profile
- Product Description
- Mechanism Of Action
- TWB-103 - Drug Profile
- Product Description
- Mechanism Of Action
- udonitrectag - Drug Profile
- Product Description
- Mechanism Of Action
- WF-10 - Drug Profile
- Product Description
- Mechanism Of Action
- Diabetic Foot Ulcers - Dormant Projects
- Diabetic Foot Ulcers - Discontinued Products
- Diabetic Foot Ulcers - Product Development Milestones
- Featured News & Press Releases
- Sep 27, 2022: Recce Pharmaceuticals announces expansion and acceleration of clinical programs
- Sep 26, 2022: CellResearch to present promising new stem cell products for the treatment of chronic diabetic foot ulcers at the world's premier diabetic foot conference (DFCon) in Los Angeles
- Sep 19, 2022: Ceria Therapeutics awarded a $300,000 SBIR Grant to advance development of a novel treatment of non-healing diabetic foot ulcers
- Sep 16, 2022: CellResearch (CRC) announces positive results of phase I study for CorLiCyte
- Aug 10, 2022: Promore Pharma granted EU patent regarding treatment of chronic wounds
- Jul 07, 2022: Destiny Pharma announces publication of XF-73 drug synergy data
- Apr 21, 2022: Cynata advances clinical trial in Diabetic Foot Ulcers
- Apr 12, 2022: MediWound's EscharEx highlighted in poster and oral presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
- Apr 05, 2022: Lakewood-Amedex enrolls first patient in phase 2 clinical trial for patients with chronic diabetic foot Ulcers (cDFU
- Mar 29, 2022: MediWound to present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
- Dec 22, 2021: Cynata commences DFU clinical trial
- Nov 04, 2021: TechnoPhage announces first clinical safety results with innovative biological product TP-102
- Oct 22, 2021: Helixmith announces phase 3 study results of novel gene therapy treatment for diabetic foot ulcers at 2021 Annual Meeting of Diabetic Foot Ulcer Conference (DFCon)
- Aug 24, 2021: Another take on TP-102 Phase I/IIa Clinical Trial by Jornal Expresso
- Jul 09, 2021: MediWound announces peer-reviewed paper detailing Escharex phase 2 randomized control trial results published in the online Wound Repair and Regeneration Journal
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Diabetic Foot Ulcers, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Diabetic Foot Ulcers - Dormant Projects, 2022
- Diabetic Foot Ulcers - Discontinued Products, 2022
- Number of Products under Development for Diabetic Foot Ulcers, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alan Laboratories Inc
- Anterogen Co Ltd
- Aposcience AG
- APstem Therapeutics Inc
- AptaBio Therapeutics Inc
- Asia Stem Cell Regenerative Pharmaceutical Co
- Aurealis Therapeutics AG
- Beijing Huafeng Biotechnology Co Ltd
- Bio-Bank Corp
- Biofilm Pharma
- BioTissue Inc
- bioXXmed AG
- Blue Blood Biotech Corp
- Canton Biotechnologies Inc
- Cellics Therapeutics Inc
- Cellresearch Corp Pte Ltd
- Chiesi Farmaceutici SpA
- Chrysalis BioTherapeutics Inc
- Crescita Therapeutics Inc
- CSA Biotechnologies LLC
- Cynata Therapeutics Ltd
- Destiny Pharma Plc
- Energenesis Biomedical Co Ltd
- Health & Biotech Co Ltd
- Helixmith Co Ltd
- Hoth Therapeutics Inc
- Lakewood-Amedex Inc
- Madam Therapeutics BV
- Mallinckrodt Plc
- MangoGen Pharma Inc
- MediWound Ltd
- MimeTech Srl
- Mirae Cell Bio Co Ltd
- NovaLead Pharma Pvt Ltd
- OliX Pharmaceuticals Inc
- Omnio AB
- Perpetuum BV
- Pherecydes Pharma SA
- Promore Pharma AB
- Qilu Pharmaceutical Co Ltd
- Recce Pharmaceuticals Ltd
- Remedor Biomed Ltd
- RHEACELL GmbH & Co KG
- Riptide Bioscience Inc
- SaNOtize Research and Development Corp
- Scarless Laboratories Inc
- Selsym Biotech Inc
- Serodus ASA
- Shionogi & Co Ltd
- Stempeutics Research Pvt Ltd
- TechnoPhage SA
- TGV-Inhalonix Inc
- Therapeutic Systems Research Laboratories Inc
- Topadur Pharma AG
- Transwell Biotech Co Ltd
- Vasomune Inc
- Venturis Therapeutics Inc
- Vitti Labs LLC
- Zhittya Genesis Medicine Inc
- ZZ Biotech LLC
